Market Updates

Healthcare Stocks That Must Be on Your Watch List: Evoke Pharma Inc (NASDAQ:EVOK), Boston Scientific Corporation (NYSE:BSX)

Evoke Pharma Inc (NASDAQ:EVOK) shares went up 47.80% or +0.98 points to reach at $3.03 during the course of session. The stock traded in the range of $2.51 – $3.28 during its most recent trading session. The stock has total market worth of $35.32M and it has total of 9.04M outstanding shares. Relative strength index (RSI-14) for Evoke Pharma Inc (NASDAQ:EVOK) is at 39.16.

Historically the stock has climbed 62.90% in the past week and plunged -54.50% in the last four weeks, the stock illustrate that its three months performance stands at -39.28% while its year to date performance is at -8.18%. Stock’s price oscillated from $1.52 to $11.11 during past twelve months. The stock is now trading at a distance of -48.58% from SMA-20. The stock is presently trading -47.85% below from its SMA-50. In the current trading session, the stock’s price moved -30.34% below from its SMA-200. If we take a look on its volatility, 19.30 percent was seen in a week and for the month it was 16.95 percent. Stock’s ATR value is at 0.99.

Evoke Pharma Inc (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, on July 26, 2016 announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand name, “Gimoti,” for the Company’s product candidate, EVK-001 (metoclopramide nasal spray). A request for proprietary name review for Gimoti will be included if and when Evoke submits a New Drug Application (NDA) for the product candidate.

The name Gimoti (pronounced “jye-MOH-tee”) was developed in compliance with the FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names (issued in February 2010).  The development program, which included research with physicians and pharmacists, as well as an international name assessment, confirmed Gimoti is a proprietary name with strong marketing potential that is also consistent with the FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use.

Boston Scientific Corporation (NYSE:BSX) shares rose 2.87% or +0.68 points in order to take the company’s stock at the price of $24.34. Stock’s price oscillated between $23.83 and $24.79 for intra-day trading. Relative strength index (RSI-14) for Boston Scientific Corporation (NYSE:BSX) is at 62.09. It has total market capitalization of $32.59B.

Historically the stock has climbed 1.76% in the past week and soared 8.90% in the last four weeks, the stock illustrate that its three months performance stands at 11.50% while its year to date performance is at 32.00%. The stock hit the peak level of one year at $24.45 and touched the minimum level of $14.18. Shares are trading -0.45% off from the 52-week high and +71.65% above from the 52-week bottom level. The stock is now trading at a distance of 2.81% from SMA-20. The stock is presently trading 5.57% above from its SMA-50. In the current trading session, the stock’s price moved 24.43% above from its SMA-200. The company has a Return on Assets of -0.20%. The company currently has a Return on Equity of -0.60% and a Return on Investment of 0.70%.

Boston Scientific Corporation (NYSE:BSX) on July 28, 2016 reported that, its generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company’s guidance range for the quarter of $2.010 to $2.060 billion. This represents growth of 15 percent on a reported basis and 16 percent on an operational basis (calculated on a constant currency basis), all compared to the prior year period. The company reported a GAAP loss of $207 million, or $(0.15) per share, compared to earnings of $0.08 a year ago, and achieved adjusted earnings per share of $0.27 for the period, compared to $0.22 a year ago.

“Our strong performance is evidence of the success of our category leadership strategy,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “Our deep portfolio, commitment to innovation and high-performance culture are helping us meet the needs of our customers and patients while sustaining growth and momentum.”

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *

0 Shares
Share
Tweet
Share
Pin
Stumble
+1